大剂量他汀类药物临床应用的理性思考

被引：19

作者：

赵水平

胡大一

机构：

[1] 中南大学湘雅二医院心内科

[2] 北京大学人民医院心内科

来源：

中华心血管病杂志 | 2013年 / 05期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

近20年来,许多项大规模临床试验的结果一致显示,他汀类药物在冠心病的一级和二级预防中,均能显著降低心血管事件(包括心肌梗死、冠心病死亡和缺血性卒中等)的危险。他汀类药物已成为防治动脉粥样性硬化性疾病最为重要的一类药物。这类药物对心血管的益处主要是来自于降低血脂,尤其是大幅度使低密度脂蛋白胆固醇(LDL-C)降低。一、经皮冠状动脉介入(PCI)术前应用大剂量

引用

共 17 条

[1]

Statins,risk of diabetes,and implications on outcomes in the general population. Wang KL,Liu CJ,Chao TF,et al. Journal of the American College of Cardiology . 2012

[2]

Intensive lowering of LDL cholesterol with80mg versus20mg simvastatin daily in12,064survivors of myocardial infarction:a double-blind randomised trial. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH)Collaborative Group. The Lancet . 2010

[3]

Statins, Risk of Diabetes, and Implications on Outcomes in the General Population[J] . Kang-Ling Wang,Chia-Jen Liu,Tze-Fan Chao,Chi-Ming Huang,Cheng-Hsueh Wu,Su-Jung Chen,Tzeng-Ji Chen,Shing-Jong Lin,Chern-En Chiang. &nbspJournal of the American College of Cardiology . 2012 (14)

[4]

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials[J] . Cholesterol Treatment Trialists’ (CTT) Collaborators. &nbspThe Lancet . 2012 (9841)

[5]

Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies[J] . Giuseppe Patti,Christopher P. Cannon,Sabina A. Murphy,Simona Mega,Vincenzo Pasceri,Carlo Briguori,Antonio Colombo,Kyeong Ho Yun,Myung Ho Jeong,Jung-Sun Kim,Donghoon Choi,Huseyin Bozbas,Masayoshi Kinoshita,Keiichi Fukuda,Xin-Wei Jia,Hidehiko Hara,Serkan Cay,Germano Di Sciascio. &nbspCirculation . 2011 (15)

[6]

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials[J] . Naveed Sattar,David Preiss,Heather M Murray,Paul Welsh,Brendan M Buckley,Anton JM de Craen,Sreenivasa Rao Kondapally Seshasai,John J McMurray,Dilys J Freeman,J Wouter Jukema,Peter W Macfarlane,Chris J Packard,David J Stott,Rudi G Westendorp,James Shepherd,Barry R Davis,Sara L Pressel,Roberto Marchioli,Rosa Maria Marfisi,Aldo P Maggioni,Luigi Tavazzi,Gianni Tognoni,John Kjekshus,Terje R Pedersen,

[7]

Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study[J] . Vincenzo Pasceri,Giuseppe Patti,Annunziata Nusca,Christian Pristipino,Giuseppe Richichi,Germano Di Sciascio. &nbspCirculation . 2004 (6)

[8]

Clinical benefit of statinpretreatment in patients undergoing percutaneous coronary interven-tion:a collaborative patient-level meta-analysis of 13 randomizedstudies. Patti G,Cannon CP,Murphy SA,et al. Circulation . 2011

[9]

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. De Lemos JA,Blazing MA,Wiviott SD,et al. Journal of the American Medical Association, The . 2004

[10]

Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Pasceri V,Patti G,Nusca A,et al. Circulation . 2004

← 1 2 →